US Patent Issued to Principia Biopharma on Sept. 9 for "Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-dpyrimidin-1-ylpiperidine-1-carbonyl-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-ylpent-2-enenitrile" (California Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,176, issued on Sept. 9, was assigned to Principia Biopharma Inc. (Bridgewater, N.J.).

"Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-dpyrimidin-1-ylpiperidine-1-carbonyl-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-ylpent-2-enenitrile" was invented by Pasit Phiasivongsa (Hillsborough, Calif.), Kolbot By (San Ramon, Calif.) and Jean Baum (San Bruno, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Crystalline forms of Compound (I):are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) an...